EDG-5506 Targets Fast Skeletal Myosin to Protect Dystrophic Muscle and Reduce Muscle Damage Biomarkers in a Phase 1 Trial in Becker Muscular Dystrophy (BMD)

J Donovan, N Kilburn, G Gordon, B Barthel, M DuVall, A Bronson, A Russell, C Sherman, M Evanchik
Edgewise Therapeutics, Boulder, CO

Acknowledgments
The authors are grateful to the participants in the trial

Disclaimer
EDG-5506 is an investigational drug that is not approved in any territory. The authors are employees or consultants for Edgewise Therapeutics and may hold stock and/or stock options

Presented at the World Muscle Society, Halifax Nova Scotia, October 2022